<p>Kodiak Sciences Inc. (NASDAQ:KOD - 获取免费报告) 的股价在周二下跌了 4.2%。该股票最低交易价为 24.60 美元，最后交易价为 25.05 美元。在午间交易中，约有 101,949 股易手，较平均每日交易量 576,602 股下降了 82%。该股票此前收盘价为 26.14 美元。</p>
<p>获取 <strong>Kodiak Sciences</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>多家研究机构对 KOD 发布了报告。HC Wainwright 将 Kodiak Sciences 的目标股价从 24.00 美元上调至 26.00 美元，并在 11 月 17 日的报告中给予该公司 “买入” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Kodiak Sciences 的 “卖出（e+）” 评级。巴克莱将 Kodiak Sciences 的评级从 “减持” 上调至 “持平”，并在 9 月 25 日的研究报告中将该股票的目标股价从 7.00 美元上调至 17.00 美元。杰富瑞金融集团在 9 月 22 日的研究报告中开始覆盖 Kodiak Sciences，设定了 “买入” 评级和 15.00 美元的目标价。最后，Chardan Capital 在 11 月 17 日的研究报告中重申了 “中性” 评级，并对 Kodiak Sciences 的股票设定了 14.00 美元的目标价。四位股票研究分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Kodiak Sciences 的平均评级为 “持有”，共识目标价为 22.67 美元。</p>
<p><strong>查看我们最新的 KOD 股票报告</strong></p>
<h2>Kodiak Sciences 股票表现</h2>
<p>该公司的市值为 13.5 亿美元，市盈率为-6.15，贝塔值为 2.68。该公司的 50 日移动平均价格为 18.49 美元，200 日移动平均价格为 11.08 美元。</p>
<p>Kodiak Sciences (NASDAQ:KOD - 获取免费报告) 最近于 11 月 13 日发布了其财报。该公司报告每股收益（EPS）为-1.16 美元，低于分析师共识预期的-1.07 美元，差距为 0.09 美元。整体来看，股票分析师预计 Kodiak Sciences Inc.在本年度将发布-3.45 美元的每股收益。</p>
<h2>对 Kodiak Sciences 的对冲基金观点</h2>
<p>机构投资者和对冲基金最近增加或减少了对该股票的持仓。US Bancorp DE 在第一季度将其在 Kodiak Sciences 的持股增加了 131.7%。US Bancorp DE 现在拥有 9,282 股该公司的股票，价值 26,000 美元，此前在上个季度又购买了 5,276 股。Headlands Technologies LLC 在第二季度将其在 Kodiak Sciences 的持股增加了 256.4%。Headlands Technologies LLC 现在拥有 8,083 股该公司的股票，价值 30,000 美元，此前在上个季度又收购了 5,815 股。Walleye Capital LLC 在第一季度获得了 Kodiak Sciences 的一个新头寸，价值 49,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Kodiak Sciences 的持股增加了 21.7%。Vanguard Personalized Indexing Management LLC 现在拥有 15,070 股该公司的股票，价值 56,000 美元，此前在上个季度又购买了 2,691 股。最后，Russell Investments Group Ltd.在第一季度将其在 Kodiak Sciences 的持股增加了 729.9%。Russell Investments Group Ltd.现在拥有 21,039 股该公司的股票，价值 59,000 美元，此前在上个季度又购买了 18,504 股。机构投资者持有该公司 89.06% 的股票。</p>
<h2>关于 Kodiak Sciences</h2>
<p>(获取免费报告)</p>
<p>Kodiak Sciences Inc.是一家临床阶段的生物制药公司，研究、开发和商业化治疗视网膜疾病的疗法。其主要产品候选药物为 tarcocimab tedromer (KSI-301)，这是一种抗血管内皮生长因子抗体生物聚合物，目前正在进行治疗湿性年龄相关性黄斑变性（AMD）的 IIb/III 期临床研究，以及用于治疗糖尿病性黄斑水肿、视网膜静脉阻塞引起的初发黄斑水肿和非增殖性糖尿病视网膜病变的 III 期临床研究。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Kodiak Sciences 更好</li>
<li>投资于高市盈率成长股</li>
<li>Carvana 从低点上涨超过 10,000%——现在它进入了标准普尔 500 指数</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>UiPath 因财报激增：投资者应该追逐这一势头吗？</li>
<li>如何捕捉股息增加的好处</li>
<li>Pure Storage 下跌 27%：真正的机会还是应得的修正？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Kodiak Sciences 吗？</h2>
<p>在你考虑 Kodiak Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Kodiak Sciences 并不在名单上。</p>
<p>虽然 Kodiak Sciences 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Kodiak Sciences（纳斯达克代码：KOD）股票下跌 4.2%，至 25.05 美元，交易量较平均水平下降 82%。分析师的评级意见不一，普遍目标价为 22.67 美元。该公司报告的季度每股收益为（1.16 美元），未达到预期。机构投资者持有 89.06% 的股份。Kodiak Sciences 专注于视网膜疾病治疗，其主要产品正在进行 IIb/III 期临床试验</p>

<p>Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report)'s share price dropped 4.2% on Tuesday . The stock traded as low as $24.60 and last traded at $25.05. Approximately 101,949 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 576,602 shares. The stock had previously closed at $26.14.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc. (NASDAQ:KOD - 获取免费报告) 的股价在周二下跌了 4.2%。该股票最低交易价为 24.60 美元，最后交易价为 25.05 美元。在午间交易中，约有 101,949 股易手，较平均每日交易量 576,602 股下降了 82%。该股票此前收盘价为 26.14 美元。</p>
</div><p>Get <strong>Kodiak Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kodiak Sciences</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research firms have issued reports on KOD. HC Wainwright boosted their price objective on shares of Kodiak Sciences from $24.00 to $26.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 17th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Kodiak Sciences in a research report on Wednesday, October 8th. Barclays upgraded Kodiak Sciences from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and raised their price objective for the stock from $7.00 to $17.00 in a research note on Thursday, September 25th. Jefferies Financial Group began coverage on Kodiak Sciences in a research report on Monday, September 22nd. They set a &#34;buy&#34; rating and a $15.00 target price for the company. Finally, Chardan Capital restated a &#34;neutral&#34; rating and issued a $14.00 price target on shares of Kodiak Sciences in a research report on Monday, November 17th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Kodiak Sciences has an average rating of &#34;Hold&#34; and a consensus price target of $22.67.</p>
<div class="lb-trans"><p>多家研究机构对 KOD 发布了报告。HC Wainwright 将 Kodiak Sciences 的目标股价从 24.00 美元上调至 26.00 美元，并在 11 月 17 日的报告中给予该公司 “买入” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Kodiak Sciences 的 “卖出（e+）” 评级。巴克莱将 Kodiak Sciences 的评级从 “减持” 上调至 “持平”，并在 9 月 25 日的研究报告中将该股票的目标股价从 7.00 美元上调至 17.00 美元。杰富瑞金融集团在 9 月 22 日的研究报告中开始覆盖 Kodiak Sciences，设定了 “买入” 评级和 15.00 美元的目标价。最后，Chardan Capital 在 11 月 17 日的研究报告中重申了 “中性” 评级，并对 Kodiak Sciences 的股票设定了 14.00 美元的目标价。四位股票研究分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Kodiak Sciences 的平均评级为 “持有”，共识目标价为 22.67 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on KOD</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 KOD 股票报告</strong></p>
</div><h2>Kodiak Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kodiak Sciences 股票表现</h2>
</div><p>The company has a market cap of $1.35 billion, a price-to-earnings ratio of -6.15 and a beta of 2.68. The business has a fifty day moving average price of $18.49 and a 200 day moving average price of $11.08.</p>
<div class="lb-trans"><p>该公司的市值为 13.5 亿美元，市盈率为-6.15，贝塔值为 2.68。该公司的 50 日移动平均价格为 18.49 美元，200 日移动平均价格为 11.08 美元。</p>
</div><p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.09). As a group, equities analysts anticipate that Kodiak Sciences Inc. will post -3.45 EPS for the current year.</p>
<div class="lb-trans"><p>Kodiak Sciences (NASDAQ:KOD - 获取免费报告) 最近于 11 月 13 日发布了其财报。该公司报告每股收益（EPS）为-1.16 美元，低于分析师共识预期的-1.07 美元，差距为 0.09 美元。整体来看，股票分析师预计 Kodiak Sciences Inc.在本年度将发布-3.45 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Kodiak Sciences</h2>
<div class="lb-trans"><h2>对 Kodiak Sciences 的对冲基金观点</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. US Bancorp DE raised its holdings in Kodiak Sciences by 131.7% in the 1st quarter. US Bancorp DE now owns 9,282 shares of the company's stock valued at $26,000 after buying an additional 5,276 shares during the last quarter. Headlands Technologies LLC raised its stake in shares of Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock valued at $30,000 after acquiring an additional 5,815 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Kodiak Sciences during the first quarter worth $49,000. Vanguard Personalized Indexing Management LLC grew its stake in shares of Kodiak Sciences by 21.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after purchasing an additional 2,691 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Kodiak Sciences by 729.9% in the first quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company's stock worth $59,000 after purchasing an additional 18,504 shares during the last quarter. Institutional investors own 89.06% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该股票的持仓。US Bancorp DE 在第一季度将其在 Kodiak Sciences 的持股增加了 131.7%。US Bancorp DE 现在拥有 9,282 股该公司的股票，价值 26,000 美元，此前在上个季度又购买了 5,276 股。Headlands Technologies LLC 在第二季度将其在 Kodiak Sciences 的持股增加了 256.4%。Headlands Technologies LLC 现在拥有 8,083 股该公司的股票，价值 30,000 美元，此前在上个季度又收购了 5,815 股。Walleye Capital LLC 在第一季度获得了 Kodiak Sciences 的一个新头寸，价值 49,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Kodiak Sciences 的持股增加了 21.7%。Vanguard Personalized Indexing Management LLC 现在拥有 15,070 股该公司的股票，价值 56,000 美元，此前在上个季度又购买了 2,691 股。最后，Russell Investments Group Ltd.在第一季度将其在 Kodiak Sciences 的持股增加了 729.9%。Russell Investments Group Ltd.现在拥有 21,039 股该公司的股票，价值 59,000 美元，此前在上个季度又购买了 18,504 股。机构投资者持有该公司 89.06% 的股票。</p>
</div><h2>About Kodiak Sciences</h2>
<div class="lb-trans"><h2>关于 Kodiak Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc.是一家临床阶段的生物制药公司，研究、开发和商业化治疗视网膜疾病的疗法。其主要产品候选药物为 tarcocimab tedromer (KSI-301)，这是一种抗血管内皮生长因子抗体生物聚合物，目前正在进行治疗湿性年龄相关性黄斑变性（AMD）的 IIb/III 期临床研究，以及用于治疗糖尿病性黄斑水肿、视网膜静脉阻塞引起的初发黄斑水肿和非增殖性糖尿病视网膜病变的 III 期临床研究。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Kodiak Sciences</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Carvana Soars Over 10,000% From Lows—Now It’s in the S&amp;P 500</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>UiPath Surges on Earnings: Should Investors Chase the Momentum?</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Pure Storage's 27% Fall: Real Opportunity or Deserved Correction?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Kodiak Sciences 更好</li>
<li>投资于高市盈率成长股</li>
<li>Carvana 从低点上涨超过 10,000%——现在它进入了标准普尔 500 指数</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>UiPath 因财报激增：投资者应该追逐这一势头吗？</li>
<li>如何捕捉股息增加的好处</li>
<li>Pure Storage 下跌 27%：真正的机会还是应得的修正？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kodiak Sciences 吗？</h2>
</div><p>Before you consider Kodiak Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Kodiak Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Kodiak Sciences 并不在名单上。</p>
</div><p>While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kodiak Sciences 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Kodiak Sciences（NASDAQ 代码：KOD）股价下跌 4.2% - 以下是原因